Primary Care POC Diagnostics Market Forecasts to 2030 - Global Analysis By Product (Urinalysis, Ambulatory Chemistry, Infectious Diseases Testing Kits and Other Products), Technology, Sample Type, Distribution Channel, End User and By Geography

According to Stratistics MRC, the Global Primary Care POC Diagnostics Market is accounted for $16.7 billion in 2023 and is expected to reach $29.5 billion by 2030 growing at a CAGR of 8.5% during the forecast period. Primary Care Point-of-Care (POC) Diagnostics are diagnostic tools and tests used in primary care settings that enable medical professionals to get test results right away in close proximity to the patient. These tests are carried out at the point of patient care, or in close proximity to it, providing quick and easy access to diagnostic data for prompt clinical decision-making. During patient consultations, these tests enable healthcare practitioners to make prompt clinical judgments since they yield data quickly often in a matter of minutes. Maintaining high-quality testing and dependable findings in primary care settings requires POC diagnostics to ensure accuracy, dependability, and compliance with regulatory criteria.

According to the World Health Organization (WHO), approximately 354 million people globally are hepatitis B or C positive, and diagnosis and treatment are unavailable. The WHO aims to control and reduce new infections by 90% and deaths by 65% by 2030.

Market Dynamics:

Driver:

Demand for point-of-care solutions in healthcare settings

The availability of rapid testing at the point of patient care is encouraged by the need for point-of-care solutions. This allows for quick clinical choices and timely treatments during patient consultations in primary care by providing quick access to diagnostic information. This diagnostics speeds up test results considerably by removing the requirement to ship samples to centralized laboratories. This quick access to information facilitates more effective workflows in primary care settings and speeds up patient care, especially for urgent situations which further enhance the growth of the market.

Restraint:

Price pressure as a result of reduced reimbursement and financial limitations

Lower reimbursements or reimbursement for point-of-care (POC) diagnostic tests may result in higher expenses for patients or healthcare institutions. This may result in a decrease in the cost or availability of certain tests, particularly for smaller primary care clinics or underprivileged communities. Additionally, financial restrictions may force healthcare institutions to choose less expensive, lower-quality point-of-care (POC) diagnostic tests, which might compromise test range, accuracy, or reliability with stunt in the growth of the market.

Opportunity:

Demand for immediate diagnostic results

Immediate outcomes' main objective is to speed up clinical decision-making in primary care settings. Point-of-care (POC) diagnostics allow medical professionals to quickly and intelligently decide how best to treat patients at a single visit. These diagnostics drastically shorten the time it takes to get test results by doing away with the requirement for centralized laboratories. Thus, quick information availability guarantees quick interventions and speeds up the diagnostic procedure creating wide range of opportunities for the market.

Threat:

Lack of accuracy and reliability

Results from primary care point-of-care diagnostic tests that are inaccurate or untrustworthy may result in misdiagnoses, ineffective therapies, or a delay in essential actions. This might have a detrimental effect on health outcomes and jeopardize patient safety. When primary care POC diagnostic tests with a track record of errors are used by healthcare practitioners or institutions, patients may become dissatisfied or lose faith in them. Patient trust in their medical care and satisfaction may be impacted by this.

Covid-19 Impact

Demand for rapid point-of-care (POC) diagnostics surged in response to the need for quick and easily accessible SARS-CoV-2 testing. In primary care settings, procedures such molecular POC testing and lateral flow assays (LFAs) have become indispensable for rapid COVID-19 identification. Moreover, telehealth services and remote testing choices proliferated in an attempt to reduce exposure and preserve social isolation. Thus a few POC tests were modified for use in telemedicine so that patients may take tests at home under the supervision of a remote provider.

The ambulatory chemistry segment is expected to be the largest during the forecast period

The ambulatory chemistry segment is estimated to have a lucrative growth, as the term "ambulatory chemistry" describes the practice of doing biochemical analyses or chemistry tests outside of a conventional laboratory environment, usually at point-of-care (POC) or ambulatory care settings. The principal objective is to expedite and accurately collect basic biochemistry test findings to facilitate prompt clinical decision-making during patient consultations in ambulatory or primary care settings. When biochemical tests are performed in ambulatory settings, patients can visit less centralized facilities for routine testing, which can save time and facilitate diagnosis.

The lateral flow assays (LFAs) segment is expected to have the highest CAGR during the forecast period

The lateral flow assays (LFAs) segment is anticipated to witness the highest CAGR growth during the forecast period, because these tests are easy to use, quick to complete, and reasonably priced. They are intended to find out whether a certain analyze is present in biological samples like blood, urine, saliva, or other body fluids. These tests are appropriate for use in primary care or point-of-care (POC) settings where prompt findings are essential for making timely clinical choices thus encourage the growth of the market.

Region with largest share:

North America is projected to hold the largest market share during the forecast period because so many primary care facilities in the United States use POC equipment and the significant portion of this regional market has also been linked to the existence of significant firms in the nation providing goods and services for primary settings. Healthcare providers are being urged by the Centers for Medicare & Medicaid Services to start patient engagement initiatives. The market is being driven by this as well as the availability of financing for healthcare R&D by academic institutions boost the growth of the market in this region.

Region with highest CAGR:

Asia Pacific is projected to have the highest CAGR over the forecast period, owing to the availability of several cutting-edge and creative POC diagnostic solutions, the Asia-Pacific market is comparatively more developed than the rest of the globe. Another important growth driver is the increasing demand for these solutions in primary home healthcare and supported healthcare settings. This is explained by the fact that more businesses are taking use of the unrealized potential in the area. Furthermore, it is anticipated that the Asia Pacific market would develop as a result of rising public awareness of the need of early illness diagnosis to increase patient survival rates.

Key players in the market

Some of the key players profiled in the Primary Care POC Diagnostics Market include BD Biosciences, Roche Diagnostics, Abbott Laboratories, bioMerieux, Instrumentation Laboratory, Quidel Corporation, Danaher Corporation, Siemens Healthcare, Agilent Technologies, Decode Genetics, Axis-Shield, Becton Dickinson, Nova Biomedical, Trividia Health, Inc., OraSure Technologies, Inc. and Abaxis

Key Developments:

In November 2023, BD launched a new, advanced ultrasound system designed to help improve clinician efficiency when placing peripherally inserted central catheters (PICCs), central venous catheters, IV lines and other vascular access devices.

In November 2023, BD a leading global medical technology company, and Bio Farma, a state-owned life science company in Indonesia, signed a memorandum of understanding (MOU) for a joint effort to combat tuberculosis (TB)

In September 2023, bbott announced it has completed the acquisition of Bigfoot Biomedical, a leader in developing smart insulin management systems for people with diabetes.

Products Covered:

• Urinalysis
• Ambulatory Chemistry
• Infectious Diseases Testing Kits
• Lipid Testing
• Glucose Monitoring Devices
• Hematology Testing Devices
• Blood Gas/Electrolytes
• Hb1Ac Testing
• Autoimmune Disease
• Coagulation Monitoring Devices
• Cardiac Markers
• Thyroid Stimulating Hormone Devices
• Drug Abuse Testing
• Pregnancy & Fertility Testing Products
• Other Products

Technologies Covered:

• Immunoassays
• Lateral Flow Assays (LFAs)
• Molecular Diagnostics
• Clinical Chemistry
• Electrochemical & Biosensor Technologies
• Other Technologies

Sample Types Covered:

• Urine
• Blood
• Nasal & Oropharyngeal Swabs
• Other Sample Types

Distribution Channels Covered:

• Pharmacies
• Retail clinics
• E-comm. Platforms
• Other Distribution Channels

End Users Covered:

• Home Care & Self Testing
• Hospitals
• Critical Care Centers & Urgent care centers
• Ambulatory Care Facilities
• Clinical Laboratories

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances